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Many studies in different biological systems have revealed that 1α,25-dihydroxyvitamin
D3 (1α,25(OH)2D3) modulates signaling pathways triggered at the plasma membrane
by agents such as Wnt, transforming growth factor (TGF)-β, epidermal growth
factor (EGF), and others. In addition, 1α,25(OH)2D3 may affect gene expression by
paracrine mechanisms that involve the regulation of cytokine or growth factor secretion
by neighboring cells. Moreover, post-transcriptional and post-translational effects of
1α,25(OH)2D3 add to or overlap with its classical modulation of gene transcription rate.
Together, these findings show that vitamin D receptor (VDR) cannot be considered only
as a nuclear-acting, ligand-modulated transcription factor that binds to and controls the
transcription of target genes. Instead, available data support the view that much of
the complex biological activity of 1α,25(OH)2D3 resides in its capacity to interact with
membrane-based signaling pathways and to modulate the expression and secretion of
paracrine factors. Therefore, we propose that future research in the vitamin D field
should focus on the interplay between 1α,25(OH)2D3 and agents that act at the plasma
membrane, and on the analysis of intercellular communication. Global analyses such
as RNA-Seq, transcriptomic arrays, and genome-wide ChIP are expected to dissect the
interactions at the gene and molecular levels.
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INTRODUCTION
The active vitamin D metabolite 1α,25-dihydroxyvitamin D3
(1α,25(OH)2D3) is a key regulator of gene expression in higher
organisms. It modulates the activity of the vitamin D receptor
(VDR), a member of the superfamily of nuclear hormone recep-
tors that regulate gene transcription. Genome-wide chromatin
immunoprecipitation studies have shown that VDR binds to hun-
dreds of genome sites even in the absence of 1α,25(OH)2D3 and
that ligand binding increases and partially changes these binding
sites, which depend on the cell type and the duration of treat-
ment (Carlberg and Campbell, 2013). While a subset of VDR
binding sites may be responsible for the control of gene expres-
sion (VDREs or vitamin D response elements), others might
be temporary anchorage places for a population of unliganded
“dormant” VDR. According to the classical view, VDR binds
DNA as heterodimers with a retinoid X receptor (RXRα, β, or
γ) and, upon ligand binding, changes the transcription rate of
neighboring genes.
However, many genes whose expression is altered by
1α,25(OH)2D3 do not contain VDREs. Putative mechanisms of
this action include post-transcriptional regulation via changes
in the levels of microRNAs that modulate the half-life and/or
translation of their messenger RNAs (Thorne et al., 2011; Wang
et al., 2011; Alvarez-Díaz et al., 2012; Kasiappan et al., 2012;
Guan et al., 2013). Also, 1α,25(OH)2D3 may regulate genes
post-translationally via changes in the phosphorylation or other
modifications of proteins which affect their stability (Lin et al.,
2003; Li et al., 2004), or through changes in the level or activity of
proteases that target them (Alvarez-Díaz et al., 2010).
Increasing importance has recently been accorded to another
mechanism of 1α,25(OH)2D3 action: the modulation of signal-
ing pathways triggered by other agents at the plasma membrane.
Indeed, a number of studies have shown that 1α,25(OH)2D3
modulates the effects of growth factors and cytokines by altering
either their cytosolic signaling pathways or the activity of target
transcription factors in the nucleus, or even in a paracrine fashion
by inhibiting their synthesis and secretion by neighboring cells.
Here we review the available data on these non-classical,
alternative mechanisms by which 1α,25(OH)2D3 modulates
gene expression. Notably, for specific genes such as c-MYC,
both direct transcriptional and indirect modes of regulation by
1α,25(OH)2D3 have been described (Pan and Simpson, 1999;
Pálmer et al., 2001; Toropainen et al., 2010; Salehi-Tabar et al.,
2012).
INTERACTION OF 1α,25(OH)2D3 WITH WNT, HEDGEHOG,
AND NOTCH PATHWAYS
Wnt, Hedgehog, and Notch signaling pathways, which have long
been known to play crucial roles during development, are now
considered critical for many tumorigenic processes in which
they function abnormally due to mutation and/or changes in
expression of components.
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Wnt factors activate several signaling pathways upon bind-
ing to different plasma membrane receptors: the canoni-
cal or Wnt/β-catenin and the non-canonical (planar polarity,
Ca2+ . . .) pathways (Clevers and Nusse, 2012). Activation of the
Wnt/β-catenin pathway by mutation of APC or AXIN tumor
suppressor genes or of CTNNB1/β-catenin oncogene together
with changes in the expression of a number of regulatory genes
(SFRPs, DICKKOPF (DKK)s. . .) is a hallmark of most colorectal
cancers and of a variable proportion of several other malig-
nancies (Clevers and Nusse, 2012). A series of studies report
that 1α,25(OH)2D3 antagonizesWnt/β-catenin signaling in colon
cancer cells by several mechanisms: the reduction of transcrip-
tionally active β-catenin/T-cell factor complexes, the induction of
β-catenin relocation from the nucleus toward the adherens junc-
tions structures at the plasma membrane, and the increase in the
level of the Wnt inhibitor DKK-1 (Pálmer et al., 2001; Shah et al.,
2006; Aguilera et al., 2007) (Figure 1). In this way, the pathway
endpoint, i.e., the activation of β-catenin target genes, is atten-
uated by 1α,25(OH)2D3 (Pálmer et al., 2001). Emphasizing the
importance of this action, an additional indirect mechanism of
Wnt/β-catenin antagonism in colon cancer has been proposed
involving IL-1β, which will be reviewed in section 1α,25(OH)2D3
and Cytokines. Although 1,25(OH)2D3 inhibits β-catenin/TCF
transcriptional activity in colon and other cancer cells, the upreg-
ulation of the Wnt/β-catenin pathway by either ligand-activated
or unliganded VDR has been described in osteoblasts and ker-
atinocytes, where it promotes bone formation and hair follicle
differentiation, respectively (Larriba et al., 2013). However, the
results reported in keratinocytes are controversial: while VDR
enhances Wnt signaling through direct binding to Lymphocyte
Enhancer-binding Factor (LEF)-1 independently of ligand and β-
catenin (Luderer et al., 2011), ligand-activated VDR is believed to
inhibit Wnt/β-catenin signaling (Bikle, 2011; Jiang et al., 2012).
Inhibition of Hedgehog (Hh) signaling by vitamin D
compounds has also been suggested. In a study combining exper-
iments in zebrafish, the yeast Pichia pastori and mouse fibrob-
lasts, secreted vitamin D3, or its precursor 7-dehydrocholesterol
(7-DHC), was shown to mediate the paracrine inhibition of
Smoothened (Smo) by Patched (Ptch)1 which leads to pathway
inactivation (Bijlsma et al., 2006). In the model proposed, which
includes the binding of vitamin D3 to Smo at high (micromo-
lar) concentrations, Hh ligands activate the pathway by blocking
the induction of the secretion of vitamin D3/7-DHC by Ptch1
(Bijlsma et al., 2006) (Figure 1). The Hh pathway is aberrantly
activated in basal cell carcinoma, the most frequent human
tumor type. Interestingly, 1α,25(OH)2D3 inhibits proliferation
and induces differentiation of mouse basal cell carcinomas and
embryonal rhabdomyosarcomas with an activated Hh pathway
due to Ptch1 deletion (Uhmann et al., 2011, 2012). As in the
previous study, 1α,25(OH)2D3 acts at the level of Smo in a VDR-
independent manner (Figure 1). Curiously, Tang et al. found
that vitamin D3 inhibits Hh and cell proliferation more effec-
tively than 7-DHC, 25(OH)D3, or 1α,25(OH)2D3 inmurine basal
cell carcinoma cells (Tang et al., 2011). Vitamin D3 also inhibits
proliferation and Hh pathway through inactivation of Smo in
cultured mouse pancreatic adenocarcinoma cells, but has no anti-
tumor activity in vivo (Brüggemann et al., 2010). A common
concern in all these studies is the high concentration of vita-
min D3 required to observe the reported effects. Research in
Vdr-deficient mice and in mouse skin explants has shown that
lack of VDR increases the expression of several components of
the Hh pathway such as Shh, Smo, Gli1, Gli2, and Ptch1, while
1α,25(OH)2D3 suppresses their expression (Bikle et al., 2013)
(Figure 1). However, the interaction between 1α,25(OH)2D3 and
Hh signaling in human skin remains to be elucidated.
Few studies link vitamin D with Notch signaling.
Differentiation of human osteoblasts with vitamin D3 and
dexamethasone distinctly affects the expression of Notch receptor
family members (Schnabel et al., 2002). In rodent osteoblasts,
the transcription factor Hes-1, which is an effector of the
Notch pathway, enhances the induction of SPP1/osteopontin
transcription by 1α,25(OH)2D3, indicating the collaboration of
1α,25(OH)2D3 and Notch pathways in bone remodeling (Shen
and Christakos, 2005) (Figure 1). Transcriptomic analyses in
human RWPE1 immortalized non-tumorigenic prostate cells
showed the reduction of the RNA levels of the NOTCH ligands
JAGGED (JAG)1, JAG2, and Delta-like (DLL)1 by 1α,25(OH)2D3
(Kovalenko et al., 2010) (Figure 1). By contrast, no changes
in the expression of NOTCH-1 and JAG1 were detected in
cultured human keratinocytes upon 1α,25(OH)2D3 treatment
(Reichrath and Reichrath, 2012). As JAG1 transcription and,
consequently, Notch signaling are upregulated by Wnt/β-catenin
in colorectal cancer cells (Rodilla et al., 2009), the repressive
effect of 1α,25(OH)2D3 on the Notch pathway in this system may
be secondary to the antagonism of the Wnt/β-catenin pathway
(Figure 1).
INTERPLAY OF 1α,25(OH)2D3 WITH AGENTS THAT TRIGGER
SIGNALING PATHWAYS VIA PLASMAMEMBRANE KINASE
RECEPTORS
There is mutual antagonism between 1α,25(OH)2D3 and epider-
mal growth factor (EGF), a potent mitogen, in primary colon
epithelial cells and in established colon (Caco-2) and breast
(T47D) tumor cell lines. This is based on the cross-inhibition of
the expression of their respective receptors, VDR and EGFR (Tong
et al., 1998, 1999). However, it is a cell type-dependent effect as
EGF increases VDR in the rat small intestine and 1α,25(OH)2D3
increases EGFR in BT-20 breast cancer cells (Bruns et al.,
1989; Desprez et al., 1991). In addition, 1α,25(OH)2D3 inhibits
EGFR signaling by increasing the level of E-cadherin protein
at the plasma membrane, which downregulates EGFR (Pálmer
et al., 2001; Andl and Rustgi, 2005), and by decreasing that of
SPROUTY-2, a cytosolic protein that reduces EGFR ubiquitina-
tion, internalization and degradation (Cabrita and Christofori,
2008; Barbáchano et al., 2010).
Transforming growth factor (TGF)-β has opposite roles in car-
cinogenesis: it inhibits proliferation of normal epithelial cells,
but it later induces epithelial-mesenchymal transition, immuno-
suppression and metastasis (Pickup et al., 2013). 1α,25(OH)2D3
induces the expression of the type I TGF-β receptor and both
agents, 1α,25(OH)2D3 and TGF-β, cooperate in Caco-2 cell
growth inhibition (Chen et al., 2002; Pálmer et al., 2003).
Moreover, Smad3, a mediator of TGF-β signaling, is a co-activator
of VDR and contributes to gene regulation by 1α,25(OH)2D3
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FIGURE 1 | Schematic representation of the multilevel crosstalk of 1α,25(OH)2D3 (1,25) with Wnt, Hedgehog, and Notch signaling pathways. For
simplicity, only main components and regulators of the pathways are shown. Explanations, details, and references can be found in the text.
(Yanagisawa et al., 1999), an effect that is abrogated by Smad7
in transfected COS-7 cells (Yanagi et al., 1999). Reinforcing
the interaction between both signaling pathways, 1α,25(OH)2D3
induces the expression of Smad anchor for receptor activation
(SARA) (Pálmer et al., 2003), which maintains the epithelial phe-
notype by recruiting Smads 2/3 to the activated TGF-β receptors
and regulates endocytic trafficking of EGFR and other proteins
(Tang et al., 2011; Kostaras et al., 2013). Notably, a recent study of
R. M. Evans’ group has revealed a genome-wide overlap of VDR
and Smad3 binding sites that is responsible for the abrogation by
VDR ligands of the TGF-β1-mediated activation of hepatic stel-
late cells during liver fibrosis (Ding et al., 2013). These authors
show that TGF-β1 signaling redistributes VDR-binding sites in
the genome and facilitates VDR binding at Smad3 profibrotic
target genes. Upon ligand activation, VDR binding at coregu-
lated genes decreases Smad3 occupancy at these sites, causing
inhibition of fibrosis (Ding et al., 2013). This is a regulatory feed-
back mechanism in which VDR ligands limit the fibrotic process
and so ensure an appropriate non-pathological tissue response.
Given the crucial roles of TGF-β in carcinogenesis, future studies
should examine whether vitamin D compounds play similar roles
in the maintenance of epithelial integrity opposing the onset of
carcinomas.
1α,25(OH)2D3 and TGF-β interact also in bone. Curiously, in
rat (UMR 106 and ROS 17/2.8) and human (MG-63) osteoblastic
cells TGF-β increases VDR expression but inhibits the stimu-
lation of osteocalcin and osteopontin transcription and RNA
levels by 1α,25(OH)2D3 (Staal et al., 1994). TGF-β exerts this
inhibitory effect by reducing the binding of VDR-RXR com-
plexes to VDREs localized in the promoter of these genes with-
out affecting the nuclear availability of VDR at least in ROS
17/2.8 cells (Staal et al., 1996). In contrast to the stimulation
of osteocalcin synthesis in human and rat cells, 1α,25(OH)2D3
decreases osteocalcin production in mouse fetal long bone cul-
tures and neonatal osteoblastic MC3T3 cells while stimulat-
ing bone resorption (Staal et al., 1998). This bone resorption
action of 1α,25(OH)2D3 is dose-dependently inhibited by TGF-β
(Staal et al., 1998).
A complex, cell type-, context- and sometimes age-dependent
relation exists between 1α,25(OH)2D3 and insulin-like growth
factors (IGF)-I and II. For instance, in C2C12 myoblasts
1α,25(OH)2D3 decreases IGF-I expression while it increases that
of IGF-II (Garcia et al., 2011). In HT29 colon carcinoma cells
several vitamin D compounds inhibit the secretion of IGF-II
thus attenuating its cell proliferation activity (Oh et al., 2001). In
addition, 1α,25(OH)2D3 blocks the mitogenic activity of insulin
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and IGF-I in MCF7 breast cancer cells, at least in part due to
the inhibition of c-FOS upregulation (Vink-van Wijngaarden
et al., 1996). 1α,25(OH)2D3 and IGF-I have also opposite effects
on mouse long bones: IGF-I increases osteocalcin production,
which is completely blocked by 1α,25(OH)2D3, and inhibits
the enhancement of bone resorption caused by 1α,25(OH)2D3
(Staal et al., 1998). Furthermore, 1α,25(OH)2D3 variably regu-
lates the expression of several IGF binding proteins (IGFBPs),
a group of molecules with pleiotropic actions that transport
IGFs and also modulate cell survival/apoptosis: 1α,25(OH)2D3
induces IGFBP3 expression in SW480-ADH colon carcinoma,
SaOS-2 osteosarcoma, PC3 prostate cancer, MCF7 breast carci-
noma and MCF-10A normal mammary cells (Pálmer et al., 2003;
Matilainen et al., 2005; Malinen et al., 2011; Brosseau et al., 2013),
IGFBP6 in SaOS-2, SW480-ADH and colon carcinomaHT29 cells
(Oh et al., 2001; Pálmer et al., 2003; Matilainen et al., 2005),
IGFBP1 and IGFBP5 in SaOS-2 and PC3 cells, and IGFBP4 in
SaOS-2 cells (Matilainen et al., 2005). Conversely, 1α,25(OH)2D3
represses IGFBP4 in HT29 and SW480-ADH cells, and IGFBP2
in HT29 cells (Oh et al., 2001; Pálmer et al., 2003). In ovarian
cells, 1α,25(OH)2D3 alone induces IGFBP1 production but, con-
versely, it enhances the inhibitory effect of insulin (Parikh et al.,
2010). Curiously, recent studies show that IGFBP3 interacts with
VDR (Li et al., 2013) and that IGFBP6 binds VDR and blocks
the induction of osteoblast differentiation by 1α,25(OH)2D3 (Cui
et al., 2011).
Cell type-dependent effects of 1α,25(OH)2D3 have also
been described for hepatocyte growth factor (HGF) signaling.
1α,25(OH)2D3 activates the HGF gene promoter and induces
HGF expression and secretion in rat NRK-49F renal intersti-
tial fibroblasts (Li et al., 2005) and in human keloid fibroblasts
(Zhang et al., 2011). Consistently with these results, vitamin D
deficiency reduces HGF and HGF receptor/c-Met expression dur-
ing liver regeneration in rats (Goupil et al., 1997). Conversely,
1α,25(OH)2D3 decreases the level of HGF RNA in human HL-60
promyelocitic leukemia cells (Inaba et al., 1993), smooth mus-
cle cells (Shalhoub et al., 2010) and MG-63 osteosarcoma cells
(Chattopadhyay et al., 2003). Moreover, the expression of c-Met
is inhibited by 1α,25(OH)2D3 in human MHCC97 hepatocel-
lular cell line (Wu et al., 2007). Curiously, 1α,25(OH)2D3 and
HGF cooperate to increase osteogenic differentiation of human
bone marrow stem cells and maturation of chondrocyte progeni-
tor cells (Grumbles et al., 1996; D’Ippolito et al., 2002; Chen et al.,
2011, 2012). Also, 1α,25(OH)2D3 andHGF additively inhibit pro-
liferation of androgen-unresponsive prostate cancer cells (Qadan
et al., 2000).
In concordance with its regulatory role in the organism,
1α,25(OH)2D3 favors physiological and homeostatic angiogen-
esis but inhibits angiogenesis in pathological conditions. Thus,
1α,25(OH)2D3 promotes myogenic differentiation of C2C12 cells
by increasing the expression of two key angiogenic factors: vas-
cular endothelial growth factor (VEGF) and fibroblast growth
factor-1 (Garcia et al., 2013). In addition, 1α,25(OH)2D3 stimu-
lates pro-angiogenic properties of endothelial progenitor cells by
increasing VEGF levels (Grundmann et al., 2012). 1α,25(OH)2D3
also upregulates VEGF expression in osteoblast-like cells but not
in breast cancer cells (Schlaeppi et al., 1997). Likewise, ED-71,
a vitamin D analog, enhances VEGF expression and promotes
angiogenesis in a murine bone marrow ablation model (Okuda
et al., 2007). Indeed, increased production of VEGF in vascu-
lar smooth muscle cells results from the activation of a VDRE
present in the VEGF gene promoter (Cardus et al., 2009). By
contrast, 1α,25(OH)2D3 downregulates hypoxia-inducible factor
(HIF)-1 and VEGF protein expression in several human colon,
prostate and breast cancer cell lines (Ben-Shoshan et al., 2007),
decreases VEGF production by human lumbar annulus cells
(Gruber et al., 2008), and protects against diabetic retinopathy in
rats by inhibiting VEGF expression in the retina (Ren et al., 2012).
1α,25(OH)2D3 also modulates the activity of signaling path-
ways mediated by other types of plasma membrane recep-
tors such us G protein-coupled receptors. Shen et al. found
that 1α,25(OH)2D3 suppresses the expression of parathyroid
hormone-related protein (PTHrP) in prostate cancer cells via a
negative VDRE localized within the non-coding region of the
gene, thus antagonizing the induction of cell proliferation and of
the expression of the pro-invasive integrin α6β4 exerted by PTHrP
signaling (Shen et al., 2007).
1α,25(OH)2D3 AND CYTOKINES
The anti-inflammatory and immunomodulatory actions, and
thus some of the anticancer and antimicrobial effects of
1α,25(OH)2D3, are mediated by the regulation of cytokine pro-
duction and/or through the control of their receptors or down-
stream signaling pathways. Globally, 1α,25(OH)2D3contributes
to the autocrine and paracrine control of innate and adaptative
immune responses (Adorini and Penna, 2008).
1α,25(OH)2D3 regulates the function of antigen-presenting
cells and T-lymphocytes. It inhibits Th1 cells differentiation
and, therefore, the secretion of Th1-type cytokines, enhances the
development of Th2 cells, and induces tolerogenic monocytes
and dendritic cells. IL-4 and IL-10 are among the commonly
increased cytokines, while IL-1, IL-2, IL-6, IL-17, tumor necro-
sis factor (TNF)-α and interferon (IFN)-γ are decreased (Adorini
and Penna, 2008).
Mechanistically, ligand-activated VDR directly downregulates
the expression of IL-10, IL-2, and IL-12B in lipopolysaccharide-
treated humanmonocytes (THP-1) through its binding to VDREs
located in the genomic regions of these genes and the recruit-
ment of the co-repressor NCOR/SMRT and histone deacetylases
(Matilainen et al., 2010a,b; Gynther et al., 2011). Remarkably, IL-
10 is downregulated by short 1α,25(OH)2D3 treatment (8 h) but
upregulated at late time points (48 h) (Matilainen et al., 2010a).
In addition, direct VDR binding to a single VDRE mediates the
upregulation of IL-8 gene by 1α,25(OH)2D3 in undifferentiated
and differentiated THP-1 cells (Ryynänen and Carlberg, 2013).
1α,25(OH)2D3 also changes the expression of target genes
in immune cells by repressing crucial transcription factors such
as nuclear factor kappa B (NFkB) and signaling pathways such
as Janus kinase-signal transducer and activator of transcription
(JAK-STAT) (Yu et al., 1995; Muthian et al., 2006; Geldmeyer-
Hilt et al., 2011). 1α,25(OH)2D3 also represses NFκB activity in
fibroblasts and adipocytes (Harant et al., 1998; Mutt et al., 2012),
and fibroblasts lacking VDR have increased NFκB activity (Sun
et al., 2006). Direct (increase in IκBα expression and reduction
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of nuclear translocation of p65) and indirect (upregulation of
IGFBP3 and clusterin) mechanisms contribute to the inhibition
of NFκB activation (Krishnan and Feldman, 2010). D. Feldman’s
group has reported that, in addition to inhibiting NFκB, the anti-
inflammatory effects of 1α,25(OH)2D3 in prostate cancer cells
include the reduction of pro-inflammatory prostaglandins (PG)
production via suppression of ciclooxygenase-2, downregulation
of PG receptors, and upregulation of 15-hydroxyprostaglandin
dehydrogenase, which inactivates PGs (Krishnan and Feldman,
2010). Moreover, 1α,25(OH)2D3 decreases the synthesis of pro-
inflammatory IL-6 through the inactivation of p38 kinase due to
the upregulation of the mitogen kinase phosphatase (MKP)5 and
the blockade of TNF-α (Krishnan and Feldman, 2010). In Jurkat
cells, the repression of IL-2 gene by 1α,25(OH)2D3 is at least par-
tially due to the blockade of NFATp/AP-1 complex formation at
a positive regulatory NFAT-1 site, which is bound by VDR-RXR
heterodimers (Alroy et al., 1995).
1α,25(OH)2D3 reduces the secretion of interleukin (IL)1-β in
THP macrophages by blocking the activation of STAT1 (Kaler
et al., 2009). As IL1-β activates the Wnt/β-catenin pathway in
colon carcinoma cells via inhibition of GSK3β activity and sub-
sequent stabilization and nuclear translocation of β-catenin, this
mechanism may contribute to the antagonism of Wnt signal-
ing by 1α,25(OH)2D3 (Kaler et al., 2009) (Figure 1). Curiously,
IL-1α is believed to be upregulated and to mediate the antiprolif-
erative effects of 1α,25(OH)2D3 in prostate progenitor/stem cells
(Maund et al., 2011).
In human osteoblasts, 1α,25(OH)2D3 completely overrules
the inhibitory effect of IFN-β on mineralization. This domi-
nant effect on osteoblast differentiation and bone formation is
reflected in the downregulation of IFN-related and -regulated
genes by 1α,25(OH)2D3 (Woeckel et al., 2012). Concomitantly,
1α,25(OH)2D3 also induces activin A, a strong inhibitor of min-
eralization, and represses follistatin, the natural antagonist of
activin A, to ensure a fine-tuned regulation of the mineralization
process (Woeckel et al., 2013b).
Recent findings have underscored the complexity of
1α,25(OH)2D3 action and its role in the antimicrobial
response as part of innate and adaptative immunity. Thus,
activation of macrophage Toll-like receptors (TLRs) by intra-
cellular bacteria such as Mycobacterium tuberculosis upregulates
VDR and CYP27B1 genes that allow the induction of the
antimicrobial peptide cathelicidin by 1α,25(OH)2D3 (Liu
et al., 2006). In monocytes, TLR activation triggers induc-
tion of defensin β4 (DEFB4) gene requiring the cooperation
between IL-1β and 1α,25(OH)2D3, which is explained by
the presence of one VDRE and two IL-1β-activatable NFkB
sites in the DEFB4 promoter (Liu et al., 2009). In addition,
1α,25(OH)2D3 is required for the antimicrobial effect of IFN-γ
in human macrophages (Fabri et al., 2011). Moreover, by
inducing the expression of TLR2 and CD14 receptors and
cathelicidin, 1α,25(OH)2D3 mediates the effect of TGF-β
favoring the response to microbial infection and wound injury
by keratinocytes (Schauber et al., 2007). These findings show
also unexpected cooperation of 1α,25(OH)2D3 with agents
(IL-1β, TGF-β, IFN-γ) that are antagonistic in other cell
types.
INTERPLAY OF 1α,25(OH)2D3/VDR WITH TRANSCRIPTION
FACTORS
Liganded or unliganded VDR interacts with or regulates the
expression of a number of transcription factors that are down-
stream effectors of different signaling pathways (Table 1). An
interesting example is the upregulation by 1α,25(OH)2D3 of
CDKN1B/p27Kip1, a cell cycle regulator gene which lacks VDREs.
1α,25(OH)2D3 was first shown to induce CDKN1B transcrip-
tion by stimulating the binding of Sp1 and NF-Y transcription
factors to the CDKN1B promoter in the myelomonocytic U937
cell line (Inoue et al., 1999). Later, direct VDR-Sp1 interac-
tion at the promoter Sp1 sites was described as responsible for
this effect (Huang et al., 2004). In addition to the enhance-
ment of transcription, 1α,25(OH)2D3 increases the stability of
p27Kip1 protein by repressing p45Skp2, an F-box protein, through
the induction of VDR-Sp1 complexes that together with his-
tone deacetylase 1 are recruited to Sp1 sites at the p45Skp2 gene
promoter (Lin et al., 2003; Li et al., 2004; Huang and Hung,
2006).
The granulocyte-macrophage colony-stimulating factor
(GM-CSF) gene is another example of unusual regulation
by 1α,25(OH)2D3. Ligand-activated VDR represses GM-CSF
through a composite DNA element recognized by Jun-Fos
heterodimers (AP-1) and nuclear factor of activated T-cells
(NFAT)1 (Towers et al., 1999). In the absence of RXR, VDR binds
to c-Jun and stabilizes AP-1 bound to DNA, which outcompetes
NFAT1 and decreases GM-CSF transcription. In Caco-2 cells,
1α,25(OH)2D3 stimulates AP-1 via activation of protein kinase
C-α, ERK and JNK leading to cell differentiation (Chen et al.,
1999).
Table 1 | Interplay between VDR and other transcription factors.
Transcription factor Biological effect References
Sp1/NF-Y Potentiation Inoue et al., 1999; Huang
et al., 2004
AP-1/NFAT1 Repression Towers et al., 1999
AP-1 Activation Chen et al., 1999
CREB Repression Yuan et al., 2007
FOXO3a, FOXO4 Activation An et al., 2010
p53 Mutual repression Stambolsky et al., 2010;
Chen et al., 2013
PPAR-α/δ Activation Sertznig et al., 2009a,b
PPAR-γ Variable Alimirah et al., 2012;
Woeckel et al., 2013a
RAR Variable Jiménez-Lara and
Aranda, 1999;
Tavera-Mendoza et al.,
2006; Anand et al., 2008;
Ng et al., 2010
ER Downregulation Krishnan et al., 2010;
Swami et al., 2013
AR Crossregulation Zhao et al., 1999; Ting
et al., 2005
PIT-1 Downregulation Seoane and
Pérez-Fernández, 2006
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In renal cells, 1α,25(OH)2D3 suppresses renin gene expres-
sion by blocking the cyclic AMP response element (CRE) through
direct binding of VDR to CRE-binding protein (CREB) and
so, inhibiting the binding of CREB to the CRE (Yuan et al.,
2007). By a complex mechanism, 1α,25(OH)2D3 also regu-
lates several Forkhead box (FOX) transcription factors. Ligand-
activated VDR binds FOXO3a and FOXO4 together with their
regulators, sirtuin 1 deacetylase and protein phosphatase 1,
inducing deacetylation and dephosphorylation of FOXO pro-
teins, thereby activating these (An et al., 2010). In the case of
the p53 tumor suppressor protein a mutual regulation takes
place: while mutated p53 interacts physically with VDR and
changes VDR-target genes, converting 1α,25(OH)2D3 from a
pro-apoptotic into an anti-apoptotic agent (Stambolsky et al.,
2010), 1α,25(OH)2D3 activates the promoter of Mdm2 in a
p53-dependent fashion promoting the expression of this nega-
tive regulator of p53 protein stability and function (Chen et al.,
2013).
Multiple interplays between 1α,25(OH)2D3/VDR and other
nuclear receptor ligands have been described. Among them,
crosstalk between liganded VDR and peroxisome proliferator-
activated receptor (PPAR)-α/δ in melanoma cells (Sertznig et al.,
2009a,b) that may involve the stimulation of PPAR-δ expres-
sion by 1α,25(OH)2D3 (Dunlop et al., 2005). A synergistic
action of 1α,25(OH)2D3 and rosiglitazone, a PPAR-γ ligand, has
been shown during osteoblast-mediated mineralization (Woeckel
et al., 2013a), while in human T47D breast cancer cells PPAR-
γ binds VDR and represses its transcriptional activity, possi-
bly also by competing for RXR heterodimerization (Alimirah
et al., 2012). Titration out of common co-activators, but not
of RXR, may be the mechanism by which ligand-bound VDR
represses retinoic acid receptor (RAR) transactivation in GH4C1
pituitary cells (Jiménez-Lara and Aranda, 1999). The relation
between 1α,25(OH)2D3 and retinoic acid is however complex,
as cooperative effects on target genes and cellular outcome (pro-
liferation inhibition and differentiation) have been described in
other systems (Tavera-Mendoza et al., 2006; Anand et al., 2008;
Ng et al., 2010). As for estrogen receptor (ER), D. Feldman’s
group has shown that 1α,25(OH)2D3 exerts a multilevel pro-
tective effect against breast cancer that includes the inhibition
of estrogen synthesis through the direct and indirect repression
of aromatase (CYP19) and the downregulation of ER-α expres-
sion through two VDREs in its promoter region (Krishnan et al.,
2010; Swami et al., 2013). Likewise, there is a complex and
unresolved relationship between 1α,25(OH)2D3 and androgen
receptor (AR) synthesis and signaling. 1α,25(OH)2D3 induces AR
in LNCaP cells (Zhao et al., 1999) while AR reduces VDR tran-
scriptional activity (Ting et al., 2005), perhaps in some cells by
a mechanism mediated by prohibitin (Mooso et al., 2010). In
addition, 1α,25(OH)2D3 inhibits glucuronidation and so, inac-
tivation of androgen in prostate cancer cells through the repres-
sion of UDP-glucuronosyltransferases (UGT) 2B15 and 2B17,
which is counterintuitive given the growth promoting action of
androgen and the antiproliferative effect of 1α,25(OH)2D3 in
prostate cancer cells (Kaeding et al., 2008). In human bladder,
1α,25(OH)2D3 and analogs inhibit cell proliferation promoted by
androgen and keratinocyte growth factor and induce apoptosis
at least in part by repressing Bcl-2 expression (Crescioli et al.,
2005).
Pituitary transcription factor (Pit)-1 activates growth hor-
mone and prolactin genes in the anterior pituitary and also in
breast cancer cells (Seoane and Pérez-Fernández, 2006). In MCF7
cells, VDR homodimers bind the PIT-1 promoter and inhibit its
expression in the presence of 1α,25(OH)2D3 without involvement
of RXR (Seoane and Pérez-Fernández, 2006).
CONCLUSIONS
The available evidence shows that the classical view of VDR only
as a nuclear-acting ligand-modulated transcription factor that
regulates the rate of transcription of those genes to which it binds
is outdated. Instead, VDR and its ligand constitute a multilevel
main regulator of gene expression in higher cells acting directly
or indirectly, and via a variety of different mechanisms, on many
signaling pathways. Some of them are triggered from the plasma
membrane by paracrine or endocrine agents, and 1α,25(OH)2D3
interacts at different levels: membrane receptors, cytosolic signal-
ing molecules or effector nuclear transcription factors. In most
cases 1α,25(OH)2D3 action is mediated by nuclear VDR but in
a few others this is unclear and non-canonical VDR-independent
or extranuclear effects have been proposed. Available studies show
that 1α,25(OH)2D3 and these signaling pathways interact vari-
ably and with distinct outcomes in a cell/tissue-specific fashion
and sometimes also differentially between normal and malignant
cells.
PERSPECTIVES
The increasingly recognized importance of its non-cell
autonomous actions has widened the scope of the study of
1α,25(OH)2D3. On the one hand, an in-depth study of the
interplay between 1α,25(OH)2D3 and other agents, which seems
to be cell-specific in terms of biological outcome, is necessary to
elucidate the possibilities of combined therapies using vitamin D
compounds and inhibitors or activators of a variety of signaling
pathways. On the other hand, several of these interactions
take place at the intercellular level. By using high-throughput
techniques and genome-wide analyses, we expect to be able to
identify secreted paracrine and intracellular mediators of the
interaction between 1α,25(OH)2D3 and other signaling pathways
responsible for the regulatory actions of 1α,25(OH)2D3 in the
organism. Future research should aim to discern how vitamin D
compounds modulate tissue and organ physiology and how they
may be used to treat pathological processes such as infections,
autoimmune disorders, or cancer.
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